Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BJ’s Wholesale Club Fourth Quarter Fiscal 2025 Earnings Call - Membership Surge, Club Buildout and Digital Lift Offset Margin Pressure
BJ’s closed fiscal 2025 with clear momentum, growing members, opening more clubs than ever, and pushing digital penetration higher, all while delivering record full-year EPS. The company added over 50...
- Membership momentum is the headline, with over 500,000 net new members in FY25, total membership topping 8 million, and a rare 90% tenured renewal rate for the fourth consecutive year.
- Management reported record full-year Adjusted EPS of $4.40, and Q4 Adjusted EPS of $0.96, up 3.2% year-over-year, hitting the high end of revised guidance for the year.
- Net sales for Q4 were approximately $5.4 billion, up 5.5% year-over-year; merchandise comparable club sales excluding gasoline rose 2.6% in Q4.
- +12 more takeaways
Lexicon Pharmaceuticals Q4 and Full Year 2025 Earnings Call - Zynquista Resubmission Planned, Multiple Clinical Catalysts in 2026
Lexicon enters 2026 with a clear, catalyst-heavy playbook: a planned NDA resubmission for Zynquista in type 1 diabetes contingent on Steno-1 exposure and DKA safety data, an on-track SONATA-HCM Phase ...
- Company summary: Lexicon is focused on three late-stage assets, sotagliflozin (cardiometabolic, HCM and T1D), pilavapadin (chronic neuropathic pain, Phase 3-ready), and LX9851 (oral obesity program now with Novo Nordisk).
- Zynquista (sotagliflozin in T1D): FDA indicated that Steno-1 investigator-initiated study data may support an NDA resubmission if prespecified patient exposure and DKA safety criteria are met, and Lexicon expects to resubmit in 2026 with a potential approval before year-end.
- Regulatory bar for DKA safety: FDA communicated a target DKA rate comparable to the inTANDEM 400 mg arm, roughly 3.5 cases per 100 patient-years, and Lexicon says current Steno-1 exposure and DKA tracking give them high confidence for submission plans.
- +12 more takeaways
Bioventus Q4 2025 Earnings Call - Scaling PNS, PRP and Ultrasonics Investments to Accelerate Growth While Preserving ~20% EBITDA
Bioventus closed 2025 with a tidy quarter and a clear playbook: tighten the core, harvest cash, then spend aggressively on new growth engines. Q4 revenue was $158 million, up 3% year-over-year and +10...
- Q4 headline, revenue $158 million, +3% year-over-year, organic growth +10% after adjusting for the Advanced Rehabilitation divestiture.
- Adjusted EBITDA $37 million in Q4, up $8 million versus prior year, representing a 30% increase and a 23% Adjusted EBITDA margin, up ~490 basis points year-over-year.
- Quarterly cash from operations reached a record ~$38 million, full-year cash from operations nearly $75 million, a ~92% increase over 2024.
- +12 more takeaways
Liquidia Corporation Full Year 2025 Earnings Call - YUTREPIA launch reached profitability and targets $1B franchise by 2027
Liquidia says its YUTREPIA launch moved from proof to profit faster than most imagined. The company reported $148.3 million in 2025 net product sales, including $90.1 million in Q4, and posted two con...
- YUTREPIA generated $148.3 million in net product sales for full year 2025, including $90.1 million in Q4.
- Q4 marked Liquidia’s second consecutive quarter of improving profitability, with non-GAAP adjusted EBITDA of $27.3 million and net income of $14.6 million.
- The company ended 2025 with $190.7 million in cash and equivalents and produced $33 million of positive cash flow in Q4, calling the business a cash-generating growth engine.
- +11 more takeaways
Seaport Entertainment Group Q4 2025 Earnings Call - 250 Water Street sale closes, ~$75M cash and Tin Building reposition to Balloon Museum to boost EBITDA
Seaport finished 2025 with a clearer runway. The company closed the long-anticipated sale of 250 Water Street in early February, unlocking roughly $75 million net proceeds and eliminating about $7 mil...
- Sale of 250 Water Street closed in early February, generating approximately $75 million net proceeds after post-closing obligations, with most of those obligations expected resolved by Q3 2026.
- Sale eliminates about $7 million of annual cash burn related to interest and carrying costs tied to 250 Water Street.
- Tin Building culinary concept with Jean-Georges closed; new 5-year initial lease with Lux Entertainment will host the Balloon Museum, with tenant fit-out at their expense and company landlord work estimated at about $5 million.
- +16 more takeaways
REGENXBIO Q4 2025 Earnings Call - RGX-202 nears pivotal readout and an accelerated approval push for Duchenne
REGENXBIO closed 2025 with a tightly focused slate of late-stage catalysts and a familiar regulatory hangover. The big headline is RGX-202 for Duchenne: pivotal dosing completed, robust phase I/II fun...
- RGX-202 (Duchenne) pivotal enrollment completed in October 2025, with top-line pivotal data expected early in Q2 2026.
- REGENXBIO plans a pre-BLA meeting with FDA mid-2026 and intends to pursue accelerated approval, supporting microdystrophin with substantial functional data.
- Phase I/II RGX-202 data show durable functional differentiation, including an average +7.4 NSAA improvement versus the CTAP model at 18 months; company stresses strong results in older patients where decline is expected.
- +12 more takeaways
Kroger Co. Q4 2025 Earnings Call - Price Investments and E-commerce Profitability Poised to Drive Share Gains
Kroger closed 2025 with improved trends and a leadership reset, pitching price investments and a store-centric e-commerce push as the twin engines to regain units and share. New CEO Greg Foran arrives...
- New CEO Greg Foran joins in April and priorities are clear: grow sales faster by combining lower prices, stronger store execution, and accelerated e-commerce.
- Kroger reported identical sales without fuel up 2.4% in Q4 and 2.9% for full-year 2025, with the final period of the year producing positive market share gains (period 13).
- Management emphasizes funding price investments from durable cost savings, saying procurement, import strategy, shrink reduction, and modernized ways of working are primary sources of savings.
- +12 more takeaways
FTC Solar Q4 2025 Earnings Call - Near-Breakeven Quarter as MSAs and Backlog Accelerate
FTC Solar closed 2025 with a clear growth inflection, reporting Q4 revenue of $32.9 million and FY revenue of $99.7 million, driven by strong commercial momentum and product wins. The quarter delivere...
- Q4 2025 revenue was $32.9 million, above the midpoint of guidance and up 26% sequentially; full-year 2025 revenue was $99.7 million, up 111% versus 2024.
- Non-GAAP gross profit for Q4 was $7.7 million, or 23.4% of revenue, the best level in company history as a public company; GAAP gross profit was $6.9 million or 21% of revenue.
- Adjusted EBITDA nearly reached breakeven in Q4, posting a loss of approximately $300,000, the strongest adjusted EBITDA result in six years.
- +11 more takeaways
Ferrellgas Partners, L.P. Q2 2026 Earnings Call - Class B Conversion Clears Path to Simpler Capital Structure and Growth
Ferrellgas turned a solid quarter into a strategic pivot. Q2 results showed disciplined execution: adjusted EBITDA rose 6% to $166.1 million, net earnings climbed to $102.2 million, and margin metrics...
- Board declared an $82.32 cash distribution per Class B Unit, approximately $107 million total, payable on or about March 13, 2026.
- Payment triggers achievement of the Class B Conversion Threshold; board approved conversion of all 1.3 million outstanding Class B Units into Class A Units on a 5 to 1 ratio after the distribution.
- Management frames the conversion as a step to reduce cost of capital and unlock capacity for growth initiatives, including power generation and autogas.
- +14 more takeaways
Invivyd Q4 2025 Earnings Call - DECLARATION Hits Enrollment, IDMC Clears Broader Enrollment; Mid-2026 Readout Intact
Invivyd reported that its DECLARATION trial for VYD2311 has reached target enrollment, with early event accrual and a safety review from the Independent Data Monitoring Committee that relaxed enrollme...
- DECLARATION trial for VYD2311 has reached target enrollment, randomized approximately 1,770 subjects in a 1:1:1 two active arms plus placebo design.
- The Independent Data Monitoring Committee reviewed unblinded safety data and recommended: allow pregnant and breastfeeding women to enroll, remove contraception requirement for women of childbearing potential, and drop prespecified safety visits at days 8, 38, and 68 post-dose.
- Management reports event accumulation in DECLARATION is underway and on track, but community attack rates remain an external variable that could change outcomes and timing.
- +12 more takeaways